A Trial to Determine if Quabodepistat is Processed Differently in Adults with Reduced Liver Function Compared to Adults with Normal Liver Function

2025-521502-18-00 Protocol 323-201-00009 Human pharmacology (Phase I) - Other Ended

Start 13 Nov 2025 · End 13 Mar 2026 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol 323-201-00009

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 32
Countries 1
Sites 2

Tuberculosis

Key facts

Sponsor
Otsuka Pharmaceutical Development & Commercialization Inc.
Participant type
Healthy volunteers, Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
13 Nov 2025 → 13 Mar 2026
Decision date (initial)
2025-09-19
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Tuberculosis

VersionLevelCodeTermSystem organ class
20.0 PT 10044755 Tuberculosis 100000004862

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Otsuka Pharmaceutical Development & Commercialization Inc.

Sponsor organisation
Otsuka Pharmaceutical Development & Commercialization Inc.
Address
2440 Research Boulevard
City
Rockville
Postcode
20850-3238
Country
United States

Scientific contact point

Organisation
Otsuka Pharmaceutical Development & Commercialization Inc.
Contact name
EU Clinical Trials Helpdesk

Public contact point

Organisation
Otsuka Pharmaceutical Development & Commercialization Inc.
Contact name
EU Clinical Trials Helpdesk

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 32 2
Rest of world 0

Investigational sites

Bulgaria

2 sites · Ended
Medical Center Comac Medical Ltd.
Medical Center Comac Medical Ltd, Ulitsa Sveti Georgi Sofiyski 3, 1606, Sofia
Medical Center Comac Medical Ltd.
Medical Center Comac Medical Ltd, Ulitsa Urvich 13, Krasno Selo District, Sofia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2025-11-13 2026-03-12 2025-11-13 2026-03-12

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-06-16 Bulgaria Acceptable
2025-09-15
2025-09-19
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-10-20 Bulgaria Acceptable
2025-09-15
2025-10-20
3 NON SUBSTANTIAL MODIFICATION NSM-2 2026-01-19 Bulgaria Acceptable
2025-09-15
2026-01-19
4 NON SUBSTANTIAL MODIFICATION NSM-3 2026-03-05 Bulgaria Acceptable
2025-09-15
2026-03-05